Keytruda Fails to Improve Overall Survival of Patients with Triple-Negative Breast Cancer, Phase 3 Trial Shows

Keytruda Fails to Improve Overall Survival of Patients with Triple-Negative Breast Cancer, Phase 3 Trial Shows
Keytruda (pembrolizumab), Merck's anti-PD-1 checkpoint blockade immunotherapy, failed to prolong the overall survival of patients with metastatic triple-negative breast cancer (TNBC) beyond that provided by chemotherapy agents, a Phase 3 trial shows. Checkpoint blockade immunotherapies are based on the principle of removing the "brakes" of our immune system and using its power to fight cancer faster and more effectively. Keytruda works by targeting and inhibiting the activity of PD-1, a receptor found on the surface of immune T-cells, so that cancer cells are not able to evade being targeted and destroyed by T-cells. After being approved by the U.S. Food and Drug Administration for the treatment of melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma (cHL), and
Subscribe or to access all post and page content.